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Abstract
Background: Epidemiologic studies suggest that LDL particle concentration (LDL-P) may remain elevated at guideline
recommended LDL cholesterol goals, representing a source of residual risk. We examined the following seven separate lipid
parameters in achieving the LDL-P goal of ,1000 nmol/L goal for very high risk secondary prevention: total cholesterol to
HDL cholesterol ratio, TC/HDL, ,3; a composite of ATP-III very high risk targets, LDL-C,70 mg/dL, non-HDL-C,100 mg/dL
and TG,150 mg/dL; a composite of standard secondary risk targets, LDL-C,100, non-HDL-C,130, TG,150; LDL
phenotype; HDL-C$40; TG,150; and TG/HDL-C,3.
Methods: We measured ApoB, ApoAI, ultracentrifugation lipoprotein cholesterol and NMR lipoprotein particle
concentration in 148 unselected primary and secondary prevention patients.
Results: TC/HDL-C,3 effectively discriminated subjects by LDL-P goal (F=84.1, p,10
26). The ATP-III very high risk
composite target (LDL-C,70, nonHDL-C,100, TG,150) was also effective (F=42.8, p,10
25). However, the standard
secondary prevention composite (LDL-C,100, non-HDL-C,130, TG,150) was also effective but yielded higher LDL-P than
the very high risk composite (F=42.0, p,10
25) with upper 95% confidence interval of LDL-P less than 1000 nmol/L.
TG,150 and TG/HDL-C,3 cutpoints both significantly discriminated subjects but the LDL-P upper 95% confidence intervals
fell above goal of 1000 nmol/L (F=15.8, p=0.0001 and F=9.7, p=0.002 respectively). LDL density phenotype neared
significance (F=2.85, p=0.094) and the HDL-C cutpoint of 40 mg/dL did not discriminate (F=0.53, p=0.47) alone or add
discriminatory power to ATP-III targets.
Conclusions: A simple composite of ATP-III very high risk lipoprotein cholesterol based treatment targets or TC/HDL-C ratio
,3 most effectively identified subjects meeting the secondary prevention target level of LDL-P,1000 nmol/L, providing a
potential alternative to advanced lipid testing in many clinical circumstances.
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Introduction
Treatment based on low density lipoprotein cholesterol (LDL-
C) levels has been the standard of care in treating patients with
cardiovascular disease and those at risk. Data from multiple trials
and studies, as summarized in the National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (NCEP ATP-III) have
demonstrated the link between LDL-C levels and cardiovascular
events as well as the corresponding impact of reducing LDL-C to
reduce cardiovascular risk [1]. However, more recently athero-
genic lipoprotein particle concentration measures such as low
density lipoprotein particle concentration (LDL-P) determined by
nuclear magnetic resonance (NMR) spectroscopy have outper-
formed LDL-C levels for prediction of vascular events in several
studies [2–8]. Additional support for measurement of atherogenic
lipoprotein particle burden has also come from consensus
statements outlining the value of apolipoprotein B (apoB) as an
alternative to LDL-P in identifying residual risk [9–11]. The
superior performance of ApoB and LDL-P is understandable given
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33692the limited ability of LDL-C to predict corresponding particle
concentration due to the heterogeneity of LDL particle size and
density, particularly in the setting of insulin resistance. This
potential limitation of LDL-C as a target of treatment is the basis
of interest in the use of advanced lipid testing modalities,
particularly in those at very high risk.
An update to the NCEP ATP-III guidelines established LDL-
C,70 mg/dL as the primary treatment target in patients with
very high risk, with secondary goals of non-HDL-C,100 mg/dL
and optimum TG,150 mg/dL [12]. Patients at very high risk are
defined as having the presence of established coronary artery
disease or equivalent secondary prevention level risk diagnosis plus
(1) multiple major risk factors (especially diabetes), (2) severe and
poorly controlled risk factors (especially continued cigarette
smoking), (3) multiple risk factors of the metabolic syndrome
(especially high triglycerides $200 mg/dL plus non-HDL-C
$130 mg/dL with low HDL-C [,40 mg/dL]), and (4) patients
with acute coronary syndromes.
12 In this context, we hypothesized
that broader consideration of LDL-C, non-HDL-C, triglycerides
(TG), and possibly the inclusion of LDL density, HDL-C, TG/
HDL-C or TC/HDL-C may reliably allow simple lipid and
lipoprotein cholesterol based targets to guide treatment to achieve
the population equivalent prevention cutpoint of LDL-
P,1000 nmol/L [13]. More specifically, we examined the
relationship and performance of the following seven discriminating
measures: TC/HDL,3, a composite of ATP-III very high risk
targets (LDL-C,70 mg/dL, non-HDL-C,100 mg/dL and
TG,150 mg/dL), a composite of standard secondary targets
(LDL-C,100, non-HDL-C,130, TG,150), LDL phenotype A
vs. A/B or B, HDL-C$40, TG,150, and TG/HDL-C,3i n
reaching an LDL-P goal of ,1000 nmol/L. TG,150 mg/dL was
used as a cutpoint per current ATP-III guidelines and is consistent
with values used in the composites. Whereas the TG/HDL-C,3
cutpoint was tested due to its association with insulin resistance in
overweight individuals [14] and density of LDL particles in type II
diabetes [15].
Methods
Informed consent was obtained from 148 patients located in
southeastern Virginia and northeastern North Carolina, serially
enrolled in an independent IRB approved protocol from a referral
cardiology/lipidology patient population. Exclusion criteria in-
cluded age ,18 years and inability to provide informed consent.
Venous blood was obtained by conventional phlebotomy and
specimens were split for concurrent measurement of lipids and
lipoproteins of interest.
Cholesterol concentration of major lipoprotein classes and
subclasses was measured using the Vertical Auto Profile (VAP)
procedure (Atherotech, Birmingham, AL). The VAP procedure
has been described in detail previously [16,17]. Briefly, the
procedure consists of three major steps. In the first step,
lipoprotein classes and subclasses are separated using a single
vertical spin density gradient ultracentrifugation. A two-layer
density gradient is prepared with 1.006 g/mL saline solution
followed the sample aliquot of serum or plasma which has been
diluted 40-fold with 1.21 g/mL KBr solution, submitted to
ultracentrifugation at 65,000 rpm for 45 minutes. In the second
step, the separated lipoprotein fractions are eluted and mixed with
colorimetric reagents allowing spectrophotometric quatitation of
cholesterol concentration by means of a proprietary continuous
flow analyzer resulting in lipoprotein cholesterol concentration
along the density gradient. In the third step, cholesterol
concentration of each major lipoprotein class and subclass is
determined by deconvolution and numerical integration of the
digitized absorbance vs. elution time curve providing cholesterol
concentrations of HDL, LDL, VLDL, Lp(a), IDL, and various
subclasses of HDL, LDL and VLDL.
The VAP procedure provides LDL modal size-density pheno-
type. The assignment of phenotype class is based upon the relative
position of the LDL cholesterol peak maximum on the eluted
absorbance curve. Total sample elution times are normalized to
200 seconds, with the normalized elution time approximately
inversely proportional to density. The LDL peak elution time
ranges to assign LDL phenotypes by VAP are derived by
comparison of LDL peak elution time values to corresponding
LDL particle size determined by 2–16% polyacrylamide gradient
gel electrophoresis (GGE) (Pacific Biometrics Inc., Seattle, WA) on
split specimens. An example comparison of VAP LDL peak
maximum time with average LDL size by GGE using scatter plot
is shown in Figure 1. LDL peak elution time #112 seconds
correspond to LDL size of #255 Au is defining small dense LDL
phenotype B. Peak elution times $116 seconds correspond to
LDL size $261 Au defining large buoyant LDL phenotype A.
Patients with LDL maximum time 112–116 seconds are consid-
ered as having intermediate LDL phenotype A/B.
The accuracy of the VAP procedure was initially validated and
is regularly calibrated against results obtained from the standard
beta quantification procedure (Core Laboratories for Clinical
Studies at Washington University, St. Louis, MO) using split
serum specimens. Typically, Pearson correlation coefficients for
lipoprotein cholesterol between the VAP procedure and beta
quantification are: total cholesterol, 0.99; HDL, 0.99; LDL, 0.98;
VLDL, 0.98; IDL, 0.78; Lp(a), 0.77; HDL2, 0.94, and HDL3,
0.91. VAP results are highly reproducible with typical between-
days coefficient of variation: total cholesterol, 2.0%; HDL
cholesterol, 2.9%; LDL cholesterol, 2.1%; VLDL cholesterol,
2.8%; IDL cholesterol, 8.2%; Lp(a) cholesterol, 9.1%; HDL2
cholesterol, 9.2%, and HDL3 cholesterol, 2.5%.
Serum lipoprotein particle concentrations were measured using
quantitative proton NMR spectroscopy [18–20] (LipoScience;
Raleigh, NC). Apo B and Apo AI measurements were performed
using Architect/C8000 instrument (Atherotech; Birmingham, AL)
and reagents (9D93-21 for Apo B and 9D92-21 for Apo AI) by
Abbott Laboratories were standardized using WHO-International
Reference Materials (SP1-01 for Apo AI and SP3-08 for Apo B) by
participating in Apolipoprotein AI and B Standardization
Program by Northwest Lipid Metabolism and Diabetes Research
Laboratories, University of Washington, Seattle, WA. Lp(a)-P was
measured as isoform independent whole particle concentration
using the Denka-Seiken assay (Denka-Seiken, Tokyo, Japan) using
the Abbott Architect/C8000 (Atherotech; Birmingham, AL).
Triglycerides were measured using standard enzymatic methods
also on the Abbott Architect/C8000 (Atherotech; Birmingham,
AL).
Statistical Analysis
Standard parametric analysis of variance (One way ANOVA)
was used to compare the performance of various lipid measures to
discriminate subjects by LDL-P goals and also to compare the
various lipid measures between LDL density phenotypes among
those patients meeting the composite very high risk ATP-III
targets. To identify significant interactions between individual lipid
measures, composite ATP-III targets and LDL density phenotype,
covariate adjustments were done using analysis of covariance
(ANCOVA). Classification performance of the various criteria was
assessed using the C-statistic calculated as the area-under-the-
curve (AUC) from LDL-P receiver operating characteristic (ROC)
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of LDL-P where sensitivity and specificity were concurrently
optimized.
Variables were log transformed as needed to meet Gaussian
distribution requirements for parametric statistical analysis.
Statistical analyses were performed using STATA 10 statistical
software (StataCorp, College Station, Texas), Statistica 9 (Statsoft,
Tulsa, Oklahoma) or Medcalc 11.5 (Medcalc Software, Maria-
kerke, Belgium). Two-sided P values less than 0.05 were
considered statistically significant.
Results
The mean age of subjects included in the analysis was 62.5 years
(SD=13 years). The cohort was 63.5% male and 36.5% female;.
The following clinically documented diagnoses were present: type
II diabetes, 15%; coronary artery disease, 63%; peripheral arterial
disease, 16%; and treated or untreated dyslipidemia in patients
referred for evaluation and treatment of dyslipidemia, not yet
prescribed treatment., 79%. Diagnoses were based on conven-
tional clinical diagnosis by patient’s treating physicians as
abstracted from the patient’s medical record. The patients were
not submitted to additional confirmatory or prospective initial
testing for diagnoses as part of the study. Lipid modifying drug
therapy included: statin, 78%; omega-3 polyunsaturated acids,
52%; nicotinic acid, 37%; ezetimibe, 29%; fibrate, 10%; bile acid
sequestrant, 3%. Subjects frequently carried multiple diagnoses or
were taking more than one lipid modifying drug.
We examined and compared the performance of a broad array
of lipid measures, including a composite target consisting of the
ATP-III very high risk secondary prevention goals (LDL-
C,70 mg/dL, non-HDL-C,100 mg/dL and TG,150 mg/
dL), TC/HDL-C,3 vs. $3, a composite of standard secondary
prevention goals (LDL-C,100, non-HDL-C,130, TG,150),
HDL-C,40 mg/dL vs. $40 mg/dL, LDL modal density by
ultracentrifugation grouped as phenotype A (large, buoyant) vs. A/
B or B (intermediate or small dense) phenotypes, TG,150 vs.
TG.150, and TG/HDL-C,3 vs. TG/HDL-C.3. These
potential univariate discriminators of LDL-P were examined
across the entire group of subjects. One way ANOVA results are
shown in Table 1.
TC/HDL-C most effectively discriminated subjects by LDL-P
goal: TC/HDL-C,3, LDL-P 841 (784–898) vs. .3, LDL-P 1364
(1272–1456) nmol/L; F=84.1, p,10
26. Achievement of the
composite target of very high risk secondary ATP-III goals (LDL-
C,70, non-HDL-C,100, TG,150) was also effective: LDL-P
845 (775–914) vs. 1276 (1189–1364) nmol/L; F=42.8, p,10
25.
The standard secondary prevention composite (LDL-C,100,
non-HDL-C,130, TG,150) resulted in somewhat higher mean
LDL-P than the very high risk composite discriminating
statistically significantly between the 2 groups, F=42.0, p,10
25.
TG,150 also effectively discriminated subjects: LDL-P 1027
(954–1101) vs. 1307 (1172–1443) but not to the LDL-P cutpoint of
1000 nmol/L; F=15.8, p=0.0001. Evaluation of TG/HDL-C,3
produced a similar result: 1036 (1057–1198) vs. 1254 (1132–1376);
F=9.7, p=0.002 respectively. Modal LDL density phenotype
yielded a nonsignificant trend: A, LDL-P 1062 (955–1169) vs. A/B
or B, 1182 (1088–1275) nmol/L; F=2.85, p=0.094 independent
of significant interaction with ATP-III classification (F=0.05,
p=0.99). The HDL-C cutpoint of 40 mg/dL did not discriminate
alone or add discriminatory power to ATP-III targets: $40 mg/
dL, LDL-P 1085 (992–1178) vs. ,40 mg/dL, 1143 (1053–1234)
nmol/L (F=0.53, p=0.47).
Secondary consideration of TC/HDL-C did not show inde-
pendent additional predictive power over the ATP-III very high
risk composite target with an expected significant interaction
between the two classification criteria (F=3.48, p=0.03). LDL
modal density phenotype showed a statistically significant trend
toward improvement in discrimination of LDL-P target (F=4.47,
p=0.04) and was independent, without interaction with the ATP-
III very high risk target (F=0.05, p=0.99).
Further analysis of adjusted LDL-P across LDL modal density
phenotype A, A/B, and B is summarized in Table 2. LDL-P tends
to increase with increasing LDL particle density class reaching
Figure 1. Typical relationship of average LDL particle size by gradient gel electrophoresis vs. VAP LDL peak maximum time density
parameter; Pearson correlation coefficient, r=0.80, p,10
26.
doi:10.1371/journal.pone.0033692.g001
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P for ln(TG), ApoB, TC/HDL-C, ApoB/ApoAI, TC/HDL-
C+ln(TG), and ApoB/ApoAI+ln(TG) reduced the effect of density
phenotype on LDL-P below the level of statistical significance.
However, when adjusted for age, HDL-C, ApoAI, LDL-C, non-
HDL-C, or a composite HDL-C+non-HDL-C+ln(TG), the effect
of density phenotype remained. Figure 2 summarizes LDL-P
means across density phenotypes with and without covariate
adjustment.
We determined optimized lipoprotein, lipoprotein cholesterol
and lipid based parameters using ROC curves to predict achieving
LDL-P,1000 nmol/L (Table 3). For TG, the optimum cutpoint
was 99 mg/dL (AUC=0.710 [0.628–0.782]); for LDL-C, the
optimum cutpoint was 65 mg/dL (AUC=0.864 [0.798–0.915]);
Table 1. Univariate Discrimination of LDL-P and Performance by Lipid Criteria.
Univariate Discriminator (n) LDL-P, nmol/L (95% CI) Performance
TC/HDL-C
,3 (67) 841 (784–898) F=84.1, p,10
26
$3 (81) 1362 (1272–1456)
Very High Risk Composite
Achieved (53) 845 (775–914) F=42.8, p,10
25
Not Achieved (95) 1276 (1189–1364)
LDL Density Phenotype
A (67) 1062 (955–1169) F=2.85, p=0.094
A/B or B (81) 1182 (1088–1275)
Secondary Prevention Composite
Achieved (74) 924 (863–985) F=42.0, p,10
25
Not Achieved (74) 1331 (1222–1440)
HDL-C
$40 mg/dL (40) 1085 (992–1178) F=0.53, p=0.47
,40 mg/dL (108) 1143 (1053–1234)
TG
,150 mg/dL (95) 1027 (954–1101) F=15.8, p=0.0001
$150 mg/dL (53) 1307 (1172–1443)
TG/HDL-C
,3 (86) 1036 (1057–1198) F=9.7, p=0.002
$3 (62) 1254 (1132–1376)
doi:10.1371/journal.pone.0033692.t001
Table 2. LDL-P across LDL density phenotype adjusted for potentially confounding covariates.
Covariate
Phenotype A,
(Mean, n=67) 95% CI
Phenotype A/B
(Mean, n=56) 95% CI
Phenotype B
(Mean, n=25) 95% CI p
Unadjusted 1075 972–1179 1109 995–1222 1308 1140–1475 0.052
age 1062 959–1165 1125 1012–1238 1307 1139–1476 0.062
HDL-C 1082 976–1189 1116 1002–1229 1276 1101–1450 0.18
ApoAI 1060 995–1165 1126 1012–1240 1310 1138–1481 0.057
ln(TG) 1106 1006–1025 1134 1028–1241 1171 1000–1242 0.81
LDL-C 1038 979–1097 1161 1097–1226 1291 1194–1388 0.00005
non-HDL-C 1054 994–1114 1169 1104–1234 1230 1133–1329 0.0034
HDL-C, non-HDL-C, ln(TG) 1070 1009–1130 1155 1091–1219 1221 1118–1324 0.036
ApoB 1087 1032–1141 1164 1104–1223 1154 1064–1245 0.14
TC/HDL-C 1106 1022–1191 1143 1051–1235 1149 1007–1292 0.80
ApoB/ApoAI 1117 1045–1190 1142 1063–1220 1122 1001–1244 0.89
TC/HDL-C, ln(TG) 1112 1026–1199 1143 1051–1236 1131 983–1280 0.89
ApoB/ApoAI, ln(TG) 1120 1046–1193 1142 1063–1222 1115 987–1242 0.89
doi:10.1371/journal.pone.0033692.t002
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(AUC=0.877 [0.813–0.925]); for HDL-C, the optimum cutpoint
was 54 mg/dL (AUC=0.596 [0.513–0.676]); for TC/HDL-C
ratio, the optimum cutpoint was 2.96 (AUC=0.877 [0.813–
0.925], Figure 3); for ApoB, the optimum cutpoint was 70 mg/dL
(AUC=0.886 [0.822–0.933]); for ApoB/ApoAI ratio, the opti-
mum cutpoint was 0.50 (AUC=0.888 [0.826–0.934]).
Separate analyses were performed to calculate the predicted
optimal LDL-P value for classification using 2 composite criterion
based classifications. The first criterion was the ATP-III very high
risk composite of LDL-C, non-HDL-C, and TG targets. The
second composite criterion was derived from the optimum
lipoprotein cholesterol and lipid univariate values from ROC
analysis for LDL-P,1000 nmol/L classification (LDL-
C=65 mg/dL, non-HDL-C=90 mg/dL, and TG=99 mg/dL)
as summarized in table 4. ATP-III very high risk composite
yielded an optimum cutpoint of 1107 nmol/L whereas the
criterion based on ROC optimized composite LDL-C, non-
HDL-C and TG predicted an optimal LDL-P cutpoint of
910 nmol/L.
Discussion
A simple composite of ATP-III very high risk lipoprotein
cholesterol based treatment targets or TC/HDL-C ratio,3
effectively identified subjects meeting the secondary prevention
target level of LDL-P,1000 nmol/L. The composite target is
particularly useful given the widespread familiarity with its
underlying parameters based on existing ATP-III lipid guidelines.
Consequently, in a general unselected clinical cohort, simple
lipoprotein cholesterol and triglyceride targets have the potential
to identify patients achieving high risk LDL-P goals without
advanced testing. These findings support the use of familiar,
simple, widely available, and well-standardized parameters as risk
metrics in evaluating very high risk secondary prevention patients.
Our study demonstrated that traditional cholesterol based
measurements can be used effectively as a proxy for an LDL-P
target. There is little contention in using LDL-C to identify
patients at higher risk for cardiovascular disease. However, the
metric’s role as a treatment target and a measure of treatment
success is a source of debate [19,21–23]. This concern is
fundamentally based on the pathophysiology of cardiovascular
disease as it directly relates to a gradient driven process: LDL
particle concentration dictates the flow of LDL particles into the
arterial wall [24], leading to subsequent subendothelial retention
of LDL and other ApoB containing lipoproteins which initiates the
pathway of atherosclerotic disease [25]. This atherogenic particle
concentration dependent process is often poorly reflected in LDL-
C values and consequently results in underestimation of risk. This
is highlighted by the considerable cardiovascular risk present even
in aggressively statin-treated patients [1,12,26–28] and by the
discordance in decline between LDL-C values and atherogenic
Figure 2. Mean LDL-P vs. LDL density phenotypes with covariate adjustments. Note that the effect of LDL modal density phenotype on
LDL-P is rendered insignificant by HDL-C, ApoB and TC/HDL-C ratio.
doi:10.1371/journal.pone.0033692.g002
Table 3. Receiver operating characteristic curve analysis of selected predictors of achieving LDL-P,1000 nmol/L target value.
Parameter AUC (95% CI) Optimum Cutpoint Sensitivity Specificity
Triglycerides, mg/dL 0.710 (0.628–0.782) 99 0.73 0.62
LDL-C, mg/dL 0.864 (0.798–0.915) 65 0.88 0.68
Non-HDL-C, mg/dL 0.877 (0.813–0.925) 90 0.79 0.79
HDL-C, mg/dL 0.596 (0.513–0.676) 54 0.81 0.43
TC/HDL-C ratio 0.877 (0.813–0.925) 2.96 0.82 0.81
ApoB, mg/dL 0.886 (0.822–0.933) 70 0.75 0.86
ApoB/ApoAI ratio 0.888 (0.826–0.934) 0.5 0.78 0.87
HDL-C results in classification significantly differ from chance, p=0.049; all others, p,0.0001.
doi:10.1371/journal.pone.0033692.t003
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LDL-P at a given LDL-C level is well-described [19,22] as well as
its impact on cardiovascular outcomes [2]. These collective
findings support the notion of residual risk present at lower
LDL-C levels and the subsequent use of alternative modalities
such as LDL-P to identify it.
Our study demonstrated that traditional cholesterol based lipid
measures can be used effectively as a proxy for LDL-P target. TC/
HDL,3 and a composite target of LDL-C, non-HDL-C, and TG
measures more accurately accounted for residual risk compared to
LDL-C alone. Our findings support the growing evidence for
using alternatives to the solely LDL-C based risk management
framework. Of note, the TC/HDL-C ratio is currently used as an
ostensible secondary treatment target in the Canadian Guidelines
for Cholesterol Management [29], but is explicitly not recom-
mended as a secondary target in ATPIII because it ‘‘will divert
priority from specific lipoprotein fractions as targets of therapy’’
[1]. Our study supports further inclusion and discussion of this
metric as new guidelines are established. While HDL-C did not
show independent additional predictive power over the ATP-III
composite target, LDL density phenotype type demonstrated a
trend toward statistical significance when considered along with
composite ATP-III very high risk targets but did not add
predictive power to the TC/HDL-C,3 criterion or similar
Apolipoprotein based criteria.
Unadjusted mean LDL-P increased across LDL density
phenotypes however this effect was ameliorated by adjustment
of the data for TC/HDL-C ratio, ApoB or ApoB/ApoAI ratio
but not simple or composites of lipid or lipoprotein cholesterol
covariates. These findings suggest that TC/HDL-C carries
information reflecting LDL density and hence particle excess
not found in simple lipid variables such as LDL-C and
nonHDL-C. Of note, ApoB outperformed non-HDL-C in this
regard, highlighting the limitation of non-HDL-C as a surrogate
for ApoB despite the strong correlation between the two
measures.
These results are consistent with broader evidence demon-
strating the predictive power of density phenotype, particularly
small, dense LDL particles’ (phenotype B) association with
higher risk of coronary heart disease [30–32]. As a result, the
added discriminatory power of LDL density phenotype,
particularly in the context of a very high risk composite ATP-
III target, should be further investigated within a larger cohort
and specifically compared head to head with a simple TC/HDL-
C criterion.
Lastly, ROC curve optimization to predict LDL-
P,1000 nmol/L using individual parameters identified cutpoints
that were lower than current ATP-III very high risk targets: LDL-
C,65 mg/dL, non-HDL-C,90 mg/dL, and TG,99 mg/dL.
Additionally, a complementary analysis optimizing a composite of
TG, LDL-C, and non-HDL-C suggests that more aggressive
lipoprotein cholesterol and TG target values than currently
recommended may be beneficial for those at highest risk to
ensure adequate reduction in atherogenic particle burden.
Limitations
Our study population was relatively small and composed of
serially collected, heterogeneous, and multiply treated patients.
These pilot study characteristics inherently limit the statistical
power and generalizability of the analysis, particularly in detecting
the contribution of LDL modal density phenotype. The heterog-
enous nature of the cohort is typical of clinical practice weighted
heavily with patients with secondary prevention level risk.
Accordingly, we focused our analysis on very high risk lipid
targets and those patients at highest risk which limits the ability to
generalize the results to lower risk or primary prevention patients.
The targets and high risk profile emphasized in this study include
the patient population most likely to undergo additional testing in
clinical practice.
Conclusion
Our study provides a potential alternative way of accounting for
atherogenic particle burden and associated risk using a composite
very high risk ATP-III target or TC/HDL-C ratio. Given the low
cost, near universal availability, and broader clinician understand-
ing of these options, they are arguably the preferred risk metrics
for most patients. Ultimately, further research is needed to refine
the indications for the incremental use of advanced measures of
atherogenic lipoprotein particle burden after intensive composite
lipid and lipoprotein cholesterol or TC/HDL-C targets have been
met in high risk prevention.
Table 4. Receiver operating characteristic curve analysis of LDL-P as a predictor of achieving composite LDL-C, non-HDL-C, and
triglyceride composite targets, ATP-III very high risk (ATP-III Composite) or composite of univariate ROC optimized LDL-P cutpoints,
nmol/L, for the same parameters (table A, ROC Optimized).
Parameter AUC (95% CI) Optimum LDL-P Cutpoint Sensitivity Specificity
ATP-III composite 0.824 (0.752–0.883) 1107 0.86 0.62
ROC Optimized composite 0.886 (0.822–0.933) 910 0.82 0.83
Classifications significantly differ from chance, p,0.0001.
doi:10.1371/journal.pone.0033692.t004
Figure 3. Receiver Operating Characteristic Curve analysis of
TC/HDL-C for achieving LDL-P,1000 nmol/L target value (solid
line) with 95% CI (broken lines). The diagonal broken line indicates
the line of random chance or no discrimination.N Indicates optimized
cutpoint for TC/HDL-C (2.96); Sensitivity 0.82; Specificity 0.81.
doi:10.1371/journal.pone.0033692.g003
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